胸腔积液细胞外囊泡作为晚期非小细胞肺癌生物标志物的研究进展

Research progress on extracellular vesicles in pleural effusion as biomarkers for advanced non-small cell lung cancer

肺癌是世界上最常见的恶性肿瘤之一,其中约80%为非小细胞肺癌(non-small cell lung cancer,NSCLC)。恶性胸腔积液作为晚期NSCLC的常见并发症,与患者的生活质量及预后息息相关。细胞外囊泡(extracellular vesicles,EVs)是由细胞释放的纳米级微粒,内含有蛋白质、核酸和脂质等成分,在血浆、胸腔积液和唾液等多种体液中存在。肿瘤相关EVs的研究为人们揭示肿瘤发生发展机制及实现EVs的临床应用开辟了新道路。近年研究发现,胸腔积液中的EVs是晚期NSCLC诊疗中的理想生物标志物。现就胸腔积液EVs作为晚期NSCLC生物标志物的研究进展作一综述,以期能展现其在NSCLC诊断、治疗、预后等方面的应用价值。

Lung cancer is one of the most common malignant tumors worldwide,with approximately 80%being non-small cell lung cancer(NSCLC).Malignant pleural effusion,a common complication of advanced NSCLC,is closely related to patients'quality of life and prognosis.Extracellular vesicles(EVs)are nanoscale particles released by cells,containing components such as proteins,nucleic acids,and lipids,and are present in various bodily fluids including plasma,pleural effusion,and saliva.The study of tumor-associated EVs has opened up new avenues for understanding the mechanisms of tumor development and realizing the clinical application of EVs.In recent years,research has found that EVs in pleural effusion are ideal biomarkers for the diagnosis and treatment of advanced NSCLC.This review aims to summarize the current progress in the research of pleural effusion EVs as biomarkers for advanced NSCLC,highlighting their potential application value in NSCLC diagnosis,treatment and prognosis.